UCB Brings Neupro(R) Back To All Patients In Europe
Published at: www.medicalnewstoday.com
-
European Commision Re-Approves Neupro For Parkinson's Disease and RLS
July 7, 2009
UCB's Neupro(R) (rotigotine) transdermal patch is back on the market in Europe for both Parkinson's Disease and RLS, which will benefit many patients with either of these disorders. Hopefully, the FDA will consider returning Neupro to the market in the United States for Parkinson's Disease and eventually for RLS. The advantage of a transdermal patch is the sustained release of lower doses of medicine,...
-
neupro is good for parkinson disease and restless legs syndrome
July 1, 2009
We are waiting for neupro as a new product with long term duration and as a patch compared to previous dopaminergic available on he market Results are very promising in both PD and RLS , therefore we need it on the EU MARKET
-
June 30, 2009
The return of Neupro will help to benefit many Patients.
- Subscribe to Updates
-
Work for one of the world's leading organizations? Get started now.
Get Intelligently Connected
with the world's leading experts
GLG's 850+ Clients Include:
- More than 70% of the world's leading
- mutual funds
- 15 of the leading 20
- global banks
- 7 of the leading 10
- global private equity firms
- 5 of the leading 10
- AmLaw firms
- Fortune 500® Companies
- in nearly every industry sector, including pharmaceuticals, insurance, chemicals, energy and computer software